<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00141778</url>
  </required_header>
  <id_info>
    <org_study_id>040385</org_study_id>
    <secondary_id>R01HL077389</secondary_id>
    <nct_id>NCT00141778</nct_id>
    <nct_alias>NCT00134862</nct_alias>
  </id_info>
  <brief_title>Renin-angiotensin-aldosterone System (RAAS), Inflammation, and Post-Operative Atrial Fibrillation (AF)</brief_title>
  <official_title>RAAS, Inflammation, and Post-operative AF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation (AF) is the most prevalent, sustained type of irregular heartbeat and
      affects over 2 million Americans. Post-operative AF, which leads to significant morbidity and
      a prolonged hospital stay, complicates 20% to 40% of cardiopulmonary bypass (CPB) surgical
      procedures. While recent studies indicate that interruption of the
      renin-angiotensin-aldosterone system by either angiotensin-converting enzyme (ACE) inhibition
      or AT1 receptor antagonism decreases the incidence of AF following a heart attack or
      cardioversion (electric shock to the heart), its effect on the incidence of post-operative AF
      has not been throughly studied. Studies in both animals and humans suggest that
      inflammation-induced atrial remodeling plays an important role in the cause of AF. Recent
      studies also provide evidence that activation of the renin-angiotensin-aldosterone system
      induces inflammation, myocyte injury, proarrhythmic electrical remodeling, and fibrosis
      through aldosterone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AF is the most prevalent, sustained type of irregular heartbeat and affects over 2 million
      Americans. Post-operative atrial fibrillation(AF), which leads to significant morbidity and a
      prolonged hospital stay, complicates 20% to 40% of CPB surgical procedures. While recent
      studies indicate that interruption of the renin-angiotensin-aldosterone system by either
      angiotensin-converting enzyme(ACE) inhibition or angiotensin II subtype 1 (AT1) receptor
      antagonism decreases the incidence of AF following a heart attack or cardioversion (electric
      shock to the heart), its effect on the incidence of post-operative AF has not been throughly
      studied. Studies in both animals and humans suggest that inflammation-induced atrial
      remodeling plays an important role in the cause of AF. Recent studies also provide evidence
      that activation of the renin-angiotensin-aldosterone system induces inflammation, myocyte
      injury, proarrhythmic electrical remodeling, and fibrosis through aldosterone.

      This study will evaluate the effectiveness of ACE inhibition and aldosterone receptor
      antagonism at decreasing inflammation and AF following cardiopulmonary bypass (CPB) surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative Atrial Fibrillation</measure>
    <time_frame>Measured from admission to the ICU until discharge from hospital</time_frame>
    <description>The primary endpoint of the study was the percentage of patients with electrocardiographically confirmed AF of at least 10 secs duration at any time following the end of surgery until hospital discharge, an average from 5.7 days in the ramipril group to 6.8 days in the placebo group. Patients were monitored continuously on telemetry throughout the postoperative period until discharge. Electrocardiograms were obtained for any rhythm changes detected on telemetry monitoring, and in addition, electrocardiograms were performed preoperatively, at admission to the intensive care unit, and daily starting on postoperative day 1. All electrocardiograms and rhythm strips were reviewed in a blinded fashion by a single cardiac electrophysiologist.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Renal Failure</measure>
    <time_frame>Measured until the time of hospital discharge, from 5.7 to 6.8 days on average, depending on the study group.</time_frame>
    <description>Percentage of patients with a creatinine concentrations &gt;2.5mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypotension</measure>
    <time_frame>Measured during and after surgery, until discharge, from 5.7 to 6.8 days on average.</time_frame>
    <description>Percentage of patients with hypotension defined as a systolic blood pressure &lt;90 mmHg and/or prolonged requirement for vasopressor use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypokalemia</measure>
    <time_frame>Measured until the time of hospital discharge, which was an average of 5.7 to 6.8 days depending on the treatment arm.</time_frame>
    <description>Percentage of patients who had a serum potassium concentrations &lt;3.5 milliequivalents (mEq)/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Tracheal Extubation</measure>
    <time_frame>It is the time (in minutes) from admission to the ICU until tracheal extubation</time_frame>
    <description>It is the time in minutes that it took to extubate the patient after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital Stay (Days)</measure>
    <time_frame>Measured from the day of surgery until the time of hospital discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>Measured until the time of hospital discharge</time_frame>
    <description>The percentage of patients in each study arm who died.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>Measured until the time of hospital discharge, from 5.7 to 6.8 days on average depending on the study arm.</time_frame>
    <description>Percentage of patients in each study group who experience a cerebrovascular event, confirmed by CT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative Interleukin(IL)-6 Concentrations</measure>
    <time_frame>Perioperative period</time_frame>
    <description>Interleukin-6 was measured at several time points (see time points in table) over the course of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative Plasminogen Activator Inhibitor-1 (PAI-1) Concentrations</measure>
    <time_frame>Perioperative period</time_frame>
    <description>Plasminogen activator inhibitor-1 (PAI-1) was measured at several time points (see table) over the course of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative C-reactive Protein (CRP) Concentrations</measure>
    <time_frame>Perioperative period</time_frame>
    <description>C-reactive protein was measured at several time points (see table) over the course of the study.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">455</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matched placebo pills daily beginning 4-7 days before surgery and continuing through discharge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ramipril</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ramipril daily (2.5mg, increased to 5mg) beginning 4 to 7 days before surgery and continuing through discharge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spironolactone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Spironolactone 25mg daily beginning 4 to 7 days before surgery and continuing through discharge</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo taken once a day</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril</intervention_name>
    <description>Taken orally, once a day</description>
    <arm_group_label>Ramipril</arm_group_label>
    <other_name>Angiotensin-converting enzyme inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <description>Taken orally, once a day</description>
    <arm_group_label>Spironolactone</arm_group_label>
    <other_name>Mineralocorticoid Receptor Antagonist</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Undergoing elective valvular heart surgery, coronary artery bypass grafting

          2. If female, must be postmenopausal for at least 1 year, status-post surgical
             sterilization, or if of childbearing potential, utilizing adequate birth control and
             willing to undergo urine beta-hcg testing prior to drug treatment and throughout the
             study

        Exclusion Criteria

          1. History of AF other than remote paroxysmal AF

          2. Ejection fraction less than 30%

          3. Evidence of coagulopathy (INR greater than 1.7 without warfarin therapy)

          4. Emergency surgery

          5. History of ACE inhibitor-induced angioedema

          6. Low blood pressure (systolic blood pressure less than 100 mmHg and evidence of
             hypoperfusion)

          7. Hyperkalemia (potassium level greater than 5.0 milliequivalents (mEq)/L at study
             entry)

          8. Impaired kidney function (serum creatinine level greater than 1.6 mg/dl)

          9. Any underlying or acute disease requiring regular medication that could possibly cause
             complications or make implementation of the study or interpretation of the study
             results difficult

         10. Inability to discontinue current ACE inhibitor, AT1 receptor antagonist, or
             aldosterone receptor antagonist therapy

         11. History of alcohol or drug abuse

         12. Treatment with any investigational drug in the month prior to study entry

         13. Mental condition that makes it impossible to understand the nature, scope and possible
             consequences of the study

         14. Inability to comply with the study procedures (e.g., uncooperative attitude, inability
             to return for follow-up visits, and unlikelihood of completing the study)

         15. Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy J. Brown, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Billings FT 4th, Pretorius M, Siew ED, Yu C, Brown NJ. Early postoperative statin therapy is associated with a lower incidence of acute kidney injury after cardiac surgery. J Cardiothorac Vasc Anesth. 2010 Dec;24(6):913-20. doi: 10.1053/j.jvca.2010.03.024.</citation>
    <PMID>20599398</PMID>
  </results_reference>
  <results_reference>
    <citation>Fleming GA, Murray KT, Yu C, Byrne JG, Greelish JP, Petracek MR, Hoff SJ, Ball SK, Brown NJ, Pretorius M. Milrinone use is associated with postoperative atrial fibrillation after cardiac surgery. Circulation. 2008 Oct 14;118(16):1619-25. doi: 10.1161/CIRCULATIONAHA.108.790162. Epub 2008 Sep 29.</citation>
    <PMID>18824641</PMID>
  </results_reference>
  <results_reference>
    <citation>Pretorius M, Murray KT, Yu C, Byrne JG, Billings FT 4th, Petracek MR, Greelish JP, Hoff SJ, Ball SK, Mishra V, Body SC, Brown NJ. Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery. Crit Care Med. 2012 Oct;40(10):2805-12.</citation>
    <PMID>22824930</PMID>
  </results_reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2005</study_first_submitted>
  <study_first_submitted_qc>August 31, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2005</study_first_posted>
  <results_first_submitted>August 3, 2012</results_first_submitted>
  <results_first_submitted_qc>February 19, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 22, 2013</results_first_posted>
  <last_update_submitted>February 19, 2013</last_update_submitted>
  <last_update_submitted_qc>February 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Nancy J. Brown</investigator_full_name>
    <investigator_title>Professor of Medicine and Pharmacology</investigator_title>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>cardiac surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramipril</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Enzyme Inhibitors</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
    <mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
    <mesh_term>Mineralocorticoids</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited between 2005 and 2010 from Vanderbilt University Medical Center and Brigham and Women's Hospital</recruitment_details>
      <pre_assignment_details>One week to four days prior to surgery, patients were randomized to treatment with placebo, ramipril or spironolactone. Preexisting ACE inhibitor, angiotensin receptor blocker, or MR antagonist use was stopped at randomization. Four hundred and fifty-eight patients met inclusion and were randomized</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo Group</description>
        </group>
        <group group_id="P2">
          <title>Ramipril</title>
          <description>Angiotensin-Converting Enzyme Inhibitor Group. Ramipril was given as 2.5 mg the first 3 days followed by 5 mg/day, with the dose reduced to 2.5 mg/day on the first postoperative day only.</description>
        </group>
        <group group_id="P3">
          <title>Spironolactone</title>
          <description>Mineralocorticoid Receptor (MR) Antagonist Group.Spironolactone was given as 25 mg/day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomization Prior to Study Med</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
                <participants group_id="P2" count="153"/>
                <participants group_id="P3" count="153"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
                <participants group_id="P2" count="151"/>
                <participants group_id="P3" count="147"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Started Study Medication</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
                <participants group_id="P2" count="151"/>
                <participants group_id="P3" count="147"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="145"/>
                <participants group_id="P2" count="144"/>
                <participants group_id="P3" count="143"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Met safety criteria for discontinuation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Difficulty Swallowing</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Chest Discomfort</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo Group</description>
        </group>
        <group group_id="B2">
          <title>Ramipril</title>
          <description>Angiotensin-converting enzyme inhibitor group</description>
        </group>
        <group group_id="B3">
          <title>Spironolactone</title>
          <description>Mineralocorticoid Receptor (MR) Antagonist group</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="147"/>
            <count group_id="B2" value="151"/>
            <count group_id="B3" value="147"/>
            <count group_id="B4" value="445"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B4" value="294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.0" spread="12.0"/>
                    <measurement group_id="B2" value="58.7" spread="12.3"/>
                    <measurement group_id="B3" value="59.2" spread="12.3"/>
                    <measurement group_id="B4" value="59.3" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="96"/>
                    <measurement group_id="B4" value="296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="147"/>
                    <measurement group_id="B2" value="151"/>
                    <measurement group_id="B3" value="147"/>
                    <measurement group_id="B4" value="445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Postoperative Atrial Fibrillation</title>
        <description>The primary endpoint of the study was the percentage of patients with electrocardiographically confirmed AF of at least 10 secs duration at any time following the end of surgery until hospital discharge, an average from 5.7 days in the ramipril group to 6.8 days in the placebo group. Patients were monitored continuously on telemetry throughout the postoperative period until discharge. Electrocardiograms were obtained for any rhythm changes detected on telemetry monitoring, and in addition, electrocardiograms were performed preoperatively, at admission to the intensive care unit, and daily starting on postoperative day 1. All electrocardiograms and rhythm strips were reviewed in a blinded fashion by a single cardiac electrophysiologist.</description>
        <time_frame>Measured from admission to the ICU until discharge from hospital</time_frame>
        <population>Four hundred fifty-eight patients were randomized. Of these 445 took study medication and were included in the intention-to-treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo Group</description>
          </group>
          <group group_id="O2">
            <title>Ramipril</title>
            <description>Angiotensin-converting enzyme inhibitor group</description>
          </group>
          <group group_id="O3">
            <title>Spironolactone</title>
            <description>Mineralocorticoid Receptor (MR) Antagonist group</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Atrial Fibrillation</title>
          <description>The primary endpoint of the study was the percentage of patients with electrocardiographically confirmed AF of at least 10 secs duration at any time following the end of surgery until hospital discharge, an average from 5.7 days in the ramipril group to 6.8 days in the placebo group. Patients were monitored continuously on telemetry throughout the postoperative period until discharge. Electrocardiograms were obtained for any rhythm changes detected on telemetry monitoring, and in addition, electrocardiograms were performed preoperatively, at admission to the intensive care unit, and daily starting on postoperative day 1. All electrocardiograms and rhythm strips were reviewed in a blinded fashion by a single cardiac electrophysiologist.</description>
          <population>Four hundred fifty-eight patients were randomized. Of these 445 took study medication and were included in the intention-to-treat analysis.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="151"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.2"/>
                    <measurement group_id="O2" value="27.8"/>
                    <measurement group_id="O3" value="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Discrete variables were compared among treatment groups with a chi-square test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.95</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Renal Failure</title>
        <description>Percentage of patients with a creatinine concentrations &gt;2.5mg/dl</description>
        <time_frame>Measured until the time of hospital discharge, from 5.7 to 6.8 days on average, depending on the study group.</time_frame>
        <population>The intention-to-treat analysis included anyone who had received any study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo Group</description>
          </group>
          <group group_id="O2">
            <title>Ramipril</title>
            <description>Angiotensin-converting enzyme inhibitor group</description>
          </group>
          <group group_id="O3">
            <title>Spironolactone</title>
            <description>Mineralocorticoid Receptor (MR) Antagonist group</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Renal Failure</title>
          <description>Percentage of patients with a creatinine concentrations &gt;2.5mg/dl</description>
          <population>The intention-to-treat analysis included anyone who had received any study medication.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="151"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4"/>
                    <measurement group_id="O2" value="0.7"/>
                    <measurement group_id="O3" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypotension</title>
        <description>Percentage of patients with hypotension defined as a systolic blood pressure &lt;90 mmHg and/or prolonged requirement for vasopressor use.</description>
        <time_frame>Measured during and after surgery, until discharge, from 5.7 to 6.8 days on average.</time_frame>
        <population>The intention-to-treat analysis included anyone who had received any medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo Group</description>
          </group>
          <group group_id="O2">
            <title>Ramipril</title>
            <description>Angiotensin-converting enzyme inhibitor group</description>
          </group>
          <group group_id="O3">
            <title>Spironolactone</title>
            <description>Mineralocorticoid Receptor (MR) Antagonist group</description>
          </group>
        </group_list>
        <measure>
          <title>Hypotension</title>
          <description>Percentage of patients with hypotension defined as a systolic blood pressure &lt;90 mmHg and/or prolonged requirement for vasopressor use.</description>
          <population>The intention-to-treat analysis included anyone who had received any medication.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="151"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4"/>
                    <measurement group_id="O2" value="10.6"/>
                    <measurement group_id="O3" value="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypokalemia</title>
        <description>Percentage of patients who had a serum potassium concentrations &lt;3.5 milliequivalents (mEq)/L</description>
        <time_frame>Measured until the time of hospital discharge, which was an average of 5.7 to 6.8 days depending on the treatment arm.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo Group</description>
          </group>
          <group group_id="O2">
            <title>Ramipril</title>
            <description>Angiotensin-converting enzyme inhibitor group</description>
          </group>
          <group group_id="O3">
            <title>Spironolactone</title>
            <description>Mineralocorticoid Receptor (MR) Antagonist group</description>
          </group>
        </group_list>
        <measure>
          <title>Hypokalemia</title>
          <description>Percentage of patients who had a serum potassium concentrations &lt;3.5 milliequivalents (mEq)/L</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="151"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6"/>
                    <measurement group_id="O2" value="13.8"/>
                    <measurement group_id="O3" value="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.14</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Tracheal Extubation</title>
        <description>It is the time in minutes that it took to extubate the patient after surgery.</description>
        <time_frame>It is the time (in minutes) from admission to the ICU until tracheal extubation</time_frame>
        <population>The intention-to-treat analysis included all patients who received any study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo Group</description>
          </group>
          <group group_id="O2">
            <title>Ramipril</title>
            <description>Angiotensin-converting enzyme inhibitor group</description>
          </group>
          <group group_id="O3">
            <title>Spironolactone</title>
            <description>Mineralocorticoid Receptor (MR) Antagonist group</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Tracheal Extubation</title>
          <description>It is the time in minutes that it took to extubate the patient after surgery.</description>
          <population>The intention-to-treat analysis included all patients who received any study medication.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="151"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1091.3" spread="3067.3"/>
                    <measurement group_id="O2" value="970.1" spread="3548.1"/>
                    <measurement group_id="O3" value="576.4" spread="761.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.56</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Hospital Stay (Days)</title>
        <time_frame>Measured from the day of surgery until the time of hospital discharge</time_frame>
        <population>The intention-to-treat analysis included anyone who had received any study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo Group</description>
          </group>
          <group group_id="O2">
            <title>Ramipril</title>
            <description>Angiotensin-converting enzyme inhibitor group</description>
          </group>
          <group group_id="O3">
            <title>Spironolactone</title>
            <description>Mineralocorticoid Receptor (MR) Antagonist group</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Hospital Stay (Days)</title>
          <population>The intention-to-treat analysis included anyone who had received any study medication.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="151"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="8.2"/>
                    <measurement group_id="O2" value="5.7" spread="3.2"/>
                    <measurement group_id="O3" value="5.8" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death</title>
        <description>The percentage of patients in each study arm who died.</description>
        <time_frame>Measured until the time of hospital discharge</time_frame>
        <population>The intention-to-treat analysis included all patients who received any study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo Group</description>
          </group>
          <group group_id="O2">
            <title>Ramipril</title>
            <description>Angiotensin-converting enzyme inhibitor group</description>
          </group>
          <group group_id="O3">
            <title>Spironolactone</title>
            <description>Mineralocorticoid Receptor (MR) Antagonist group</description>
          </group>
        </group_list>
        <measure>
          <title>Death</title>
          <description>The percentage of patients in each study arm who died.</description>
          <population>The intention-to-treat analysis included all patients who received any study medication.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="151"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="2.0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.38</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stroke</title>
        <description>Percentage of patients in each study group who experience a cerebrovascular event, confirmed by CT.</description>
        <time_frame>Measured until the time of hospital discharge, from 5.7 to 6.8 days on average depending on the study arm.</time_frame>
        <population>The intention-to-treat analysis included all those who received any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo Group</description>
          </group>
          <group group_id="O2">
            <title>Ramipril</title>
            <description>Angiotensin-converting enzyme inhibitor group</description>
          </group>
          <group group_id="O3">
            <title>Spironolactone</title>
            <description>Mineralocorticoid Receptor (MR) Antagonist group</description>
          </group>
        </group_list>
        <measure>
          <title>Stroke</title>
          <description>Percentage of patients in each study group who experience a cerebrovascular event, confirmed by CT.</description>
          <population>The intention-to-treat analysis included all those who received any study drug.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="151"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7"/>
                    <measurement group_id="O2" value="1.3"/>
                    <measurement group_id="O3" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.65</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Perioperative Interleukin(IL)-6 Concentrations</title>
        <description>Interleukin-6 was measured at several time points (see time points in table) over the course of the study</description>
        <time_frame>Perioperative period</time_frame>
        <population>All participants included in the intention-to-treat analysis who had available plasma samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo Group</description>
          </group>
          <group group_id="O2">
            <title>Ramipril</title>
            <description>Angiotensin-converting enzyme inhibitor group</description>
          </group>
          <group group_id="O3">
            <title>Spironolactone</title>
            <description>Mineralocorticoid Receptor (MR) Antagonist group</description>
          </group>
        </group_list>
        <measure>
          <title>Perioperative Interleukin(IL)-6 Concentrations</title>
          <description>Interleukin-6 was measured at several time points (see time points in table) over the course of the study</description>
          <population>All participants included in the intention-to-treat analysis who had available plasma samples.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="136"/>
                <count group_id="O3" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Initiation of surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="6.7"/>
                    <measurement group_id="O2" value="4.6" spread="7.1"/>
                    <measurement group_id="O3" value="6.6" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30min intraop</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" spread="18.4"/>
                    <measurement group_id="O2" value="20.5" spread="72.6"/>
                    <measurement group_id="O3" value="11.3" spread="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60min intraop</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" spread="20.1"/>
                    <measurement group_id="O2" value="28.8" spread="100.9"/>
                    <measurement group_id="O3" value="17.4" spread="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postop</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.0" spread="213.7"/>
                    <measurement group_id="O2" value="202.1" spread="668.7"/>
                    <measurement group_id="O3" value="145.7" spread="427.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.0" spread="143.1"/>
                    <measurement group_id="O2" value="171.0" spread="208.6"/>
                    <measurement group_id="O3" value="164.9" spread="200.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.3" spread="106.8"/>
                    <measurement group_id="O2" value="95.5" spread="90.8"/>
                    <measurement group_id="O3" value="109.6" spread="116.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Perioperative Plasminogen Activator Inhibitor-1 (PAI-1) Concentrations</title>
        <description>Plasminogen activator inhibitor-1 (PAI-1) was measured at several time points (see table) over the course of the study.</description>
        <time_frame>Perioperative period</time_frame>
        <population>PAI-1 was measured in all subjects in the intention-to-treat analysis for which plasma was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo Group</description>
          </group>
          <group group_id="O2">
            <title>Ramipril</title>
            <description>Angiotensin-converting enzyme inhibitor group</description>
          </group>
          <group group_id="O3">
            <title>Spironolactone</title>
            <description>Mineralocorticoid Receptor (MR) Antagonist group</description>
          </group>
        </group_list>
        <measure>
          <title>Perioperative Plasminogen Activator Inhibitor-1 (PAI-1) Concentrations</title>
          <description>Plasminogen activator inhibitor-1 (PAI-1) was measured at several time points (see table) over the course of the study.</description>
          <population>PAI-1 was measured in all subjects in the intention-to-treat analysis for which plasma was available.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Initiation of surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.6" spread="16.6"/>
                    <measurement group_id="O2" value="16.2" spread="11.9"/>
                    <measurement group_id="O3" value="17.3" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30min intraop</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2" spread="10.7"/>
                    <measurement group_id="O2" value="19.7" spread="12.5"/>
                    <measurement group_id="O3" value="17.3" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60min intraop</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.0" spread="10.9"/>
                    <measurement group_id="O2" value="22.0" spread="13.7"/>
                    <measurement group_id="O3" value="20.1" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postop</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" spread="24.6"/>
                    <measurement group_id="O2" value="38.9" spread="28.0"/>
                    <measurement group_id="O3" value="34.0" spread="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.2" spread="43.8"/>
                    <measurement group_id="O2" value="47.9" spread="31.4"/>
                    <measurement group_id="O3" value="48.9" spread="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.1" spread="20.4"/>
                    <measurement group_id="O2" value="25.7" spread="17.9"/>
                    <measurement group_id="O3" value="31.0" spread="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Perioperative C-reactive Protein (CRP) Concentrations</title>
        <description>C-reactive protein was measured at several time points (see table) over the course of the study.</description>
        <time_frame>Perioperative period</time_frame>
        <population>CRP was measured in all subjects from the intention-to-treat analysis for which plasma was available at those time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo Group</description>
          </group>
          <group group_id="O2">
            <title>Ramipril</title>
            <description>Angiotensin-converting enzyme inhibitor group</description>
          </group>
          <group group_id="O3">
            <title>Spironolactone</title>
            <description>Mineralocorticoid Receptor (MR) Antagonist group</description>
          </group>
        </group_list>
        <measure>
          <title>Perioperative C-reactive Protein (CRP) Concentrations</title>
          <description>C-reactive protein was measured at several time points (see table) over the course of the study.</description>
          <population>CRP was measured in all subjects from the intention-to-treat analysis for which plasma was available at those time points.</population>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="129"/>
                <count group_id="O3" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Initiation of surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="6.8"/>
                    <measurement group_id="O2" value="4.3" spread="10.8"/>
                    <measurement group_id="O3" value="3.9" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.4" spread="40.0"/>
                    <measurement group_id="O2" value="49.9" spread="38.5"/>
                    <measurement group_id="O3" value="64.3" spread="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.8" spread="137.4"/>
                    <measurement group_id="O2" value="131.0" spread="281.5"/>
                    <measurement group_id="O3" value="127.8" spread="84.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.3" spread="88.7"/>
                    <measurement group_id="O2" value="164.8" spread="416.5"/>
                    <measurement group_id="O3" value="189.4" spread="476.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.1" spread="67.3"/>
                    <measurement group_id="O2" value="105.2" spread="96.6"/>
                    <measurement group_id="O3" value="126.5" spread="95.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Duration of hospital stay, which averaged from 5.7 to 6.8 days depending on the study arm.</time_frame>
      <desc>The intention-to-treat analysis included all subjects who received any study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo Group</description>
        </group>
        <group group_id="E2">
          <title>Ramipril</title>
          <description>Angiotensin-converting enzyme inhibitor group</description>
        </group>
        <group group_id="E3">
          <title>Spironolactone</title>
          <description>Mineralocorticoid Receptor (MR) Antagonist group</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="147"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="147"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute renal failure</sub_title>
                <description>Creatinine &gt;2.5mg/dL</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="147"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="147"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="151"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="147"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="151"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <description>Potassium &lt;3.5 milliequivalents (mEq)/L postoperative day 1-4</description>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="147"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="151"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <description>Potassium &gt;5.5 milliequivalents (mEq)/L</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>We excluded patients with an ejection fraction less than 30% or a creatinine above 1.6 and therefore the results are not applicable to patients with left ventricular dysfunction or more severe chronic kidney disease.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Mias Pretorius</name_or_title>
      <organization>Vanderbilt University School of Medicine</organization>
      <phone>16153430665</phone>
      <email>mias.pretorius@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

